Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$11.03 -1.4%	$9.72	$5.05 ▼ $14.64	$573.89M	0.84	136,426 shs	63,385 shs
MRSN Mersana Therapeutics	$3.25 -2.7%	$4.47	$0.80 ▼ $9.62	$394.23M	1.5	2.21 million shs	2.39 million shs
NKTX Nkarta	$7.29 -6.4%	$10.78	$1.28 ▼ $16.24	$360.27M	0.7	1.92 million shs	730,368 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	+1.82%	+1.73%	+2.75%	+91.28%	+33.21%
MRSN Mersana Therapeutics	-5.11%	-10.22%	-32.66%	+23.25%	-21.41%
NKTX Nkarta	-0.89%	-11.48%	-36.25%	+4.99%	+61.28%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	1.556 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.0
MRSN Mersana Therapeutics	4.095 of 5 stars	4.4	1.0	4.1	2.7	2.5	0.0
NKTX Nkarta	2.7023 of 5 stars	4.5	2.0	0.0	0.0	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	3.00	Buy	$39.50	258.11% Upside
MRSN Mersana Therapeutics	2.71	Moderate Buy	$6.29	93.41% Upside
NKTX Nkarta	3.00	Buy	$17.83	144.63% Upside

Current Analyst Ratings

Latest NKTX, MRSN, and GHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
3/26/2024	NKTX Nkarta	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
3/22/2024	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $25.00
3/22/2024	NKTX Nkarta	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Outperform	$13.00 ➝ $16.00
3/22/2024	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
3/22/2024	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
3/19/2024	MRSN Mersana Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$5.00
3/5/2024	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $31.00
3/4/2024	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/1/2024	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$50.00 ➝ $39.00
2/29/2024	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$9.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	$4.94 per share	N/A
MRSN Mersana Therapeutics	$36.85M	10.70	N/A	N/A	$0.31 per share	10.48
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.57 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$35.59M	-$0.68	N/A	N/A	N/A	N/A	-15.48%	-15.01%	5/9/2024 (Estimated)
MRSN Mersana Therapeutics	-$171.67M	-$1.50	N/A	N/A	N/A	-465.80%	-282.36%	-62.64%	5/14/2024 (Estimated)
NKTX Nkarta	-$117.50M	-$2.40	N/A	N/A	N/A	N/A	-38.06%	-28.11%	5/9/2024 (Estimated)

Latest NKTX, MRSN, and GHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/21/2024	Q4 2023	NKTX Nkarta	-$0.62	-$0.57	+$0.05	-$0.57	N/A	N/A
2/29/2024	Q4 2023	GHRS GH Research	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A
2/28/2024	12/31/2023	MRSN Mersana Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$22.59 million	$10.70 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	24.49	24.49
MRSN Mersana Therapeutics	0.63	3.36	3.36
NKTX Nkarta	N/A	10.85	10.85

Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
MRSN Mersana Therapeutics	93.92%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	41.60%
MRSN Mersana Therapeutics	12.50%
NKTX Nkarta	5.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	49	52.03 million	30.38 million	Optionable
MRSN Mersana Therapeutics	123	121.30 million	106.14 million	Optionable
NKTX Nkarta	150	49.42 million	46.65 million	Optionable

NKTX, MRSN, and GHRS Headlines

Source	Headline
	Nkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo Finance finance.yahoo.com - April 18 at 8:03 PM
	Nkarta's (NKTX) Buy Rating Reiterated at Needham & Company LLC americanbankingnews.com - April 11 at 5:12 AM
	Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX) markets.businessinsider.com - April 10 at 2:40 PM
	Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT) markets.businessinsider.com - April 10 at 9:39 AM
	Needham & Company LLC Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) marketbeat.com - April 10 at 8:17 AM
	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors businesswire.com - April 8 at 12:55 PM
	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors businesswire.com - April 5 at 5:44 PM
	The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors businesswire.com - April 5 at 3:35 PM
	Nkarta to Participate in Upcoming Investor Conferences globenewswire.com - April 3 at 4:02 PM
	Nkarta (NASDAQ:NKTX) Stock Price Down 5.7% marketbeat.com - April 2 at 12:50 PM
	Nkarta (NASDAQ:NKTX) Shares Gap Up to $10.81 marketbeat.com - April 1 at 11:59 AM
	Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO 247wallst.com - March 31 at 8:55 AM
	Simeon George Purchases 2,000,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) Stock insidertrades.com - March 30 at 4:16 AM
	Nkarta, Inc. (NASDAQ:NKTX) Director Acquires $20,000,000.00 in Stock marketbeat.com - March 28 at 7:21 PM
	TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX) markets.businessinsider.com - March 27 at 5:39 AM
	Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-Hearted msn.com - March 27 at 5:39 AM
	Nkarta (NASDAQ:NKTX) Price Target Increased to $16.00 by Analysts at Canaccord Genuity Group marketbeat.com - March 26 at 8:47 AM
	Nkarta, Inc. (NKTX) interactive stock chart – Yahoo Finance sg.finance.yahoo.com - March 26 at 8:34 AM
	Nkarta: NK Cell Therapy Advancement On Two Fronts seekingalpha.com - March 25 at 5:33 PM
	Nkarta announces pricing of stock offering to raise $240.1M msn.com - March 25 at 12:32 PM
	Nkarta Prices $240 Mln Offering; Stock Up Over 16% markets.businessinsider.com - March 25 at 7:32 AM
	Nkarta Announces Pricing of $240 Million Underwritten Offering globenewswire.com - March 25 at 6:30 AM
	Nkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy Rating markets.businessinsider.com - March 25 at 2:30 AM
	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment finance.yahoo.com - March 23 at 8:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GH Research

NASDAQ:GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Mersana Therapeutics

NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Nkarta

NASDAQ:NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial